Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI filing briefs

Greenwich LifeSciences, Inc. (GLSI)

GLSI 8-K filings in 2025

Every material Form 8-K Greenwich LifeSciences, Inc. filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 202513 on record in all
Latest filing in 2025Jul 24, 2025other
High impact (4-5)0of 1 brief
ToneNeutral1
Jul 24, 4:30 PM ET

Greenwich LifeSciences dismisses auditor RBSM, hires MaloneBailey for 2025 audit

Neutral other Written later 4.01

Greenwich LifeSciences, Inc. dismissed RBSM LLP as its independent registered public accounting firm and engaged MaloneBailey LLP to audit its financial statements for the year ending December 31, 2025. RBSM's reports on the 2024 and 2023 financial statements contained no adverse opinion, disclaimer, or qualification, and the filing states there were no disagreements with RBSM. The filing notes material weaknesses in internal control over financial reporting disclosed in prior 10-K and 10-Q reports, which shareholders may want to monitor under the new auditor.

  • Audit committee approved the change on July 19, 2025; RBSM was informed it would be dismissed effective immediately.
  • RBSM's audit reports for fiscal 2024 and 2023 had no adverse opinion, disclaimer, or qualification.
  • The company cites material weaknesses in internal control over financial reporting in its 2024 and 2023 10-K reports and its 2024 and March 31, 2025 10-Q reports.
  • RBSM's letter to the SEC, dated July 22, 2025, is filed as Exhibit 16.1.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Greenwich LifeSciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →